MG

Molly Gibson

Chief Innovation Officer at Generate Biomedicines

Greater Boston

Overview 

Molly Gibson is currently an Origination Partner at Flagship Pioneering and a Co-founder of Generate Biomedicines. With a Ph.D. in Bioinformatics from Washington University School of Medicine, she has held various leadership roles in innovative biotech companies and has a strong background in computational biology and genomics. Gibson's career highlights include co-founding Generate Biomedicines and her progression from a Ph.D. candidate to an Origination Partner at Flagship Pioneering, showcasing her expertise in bioinformatics, computational biology, and strategic leadership in the biotech industry.

Work Experience 

FP

Flagship Pioneering

  • Origination Partner

    2023 - Current

  • Senior Principal

    2021 - 2023

  • Principal

    2019 - 2021

  • Senior Associate

    2018 - 2019

  • Associate

    2017 - 2018

Flagship Pioneering is a venture capital firm that invests in life sciences and healthcare companies.

flagshippioneering.com
GB

Generate Biomedicines, Inc.

  • Co-Founder

    2018

    Generate Biomedicines is an early-stage life sciences company pioneering a machine learning– powered biomedicines platform with the potential to generate new drugs on demand across a wide range of biologic modalities—from short peptides to complex antibodies, enzymes, cytokines, and yet to be described protein compositions. Generate Biomedicine’s multimodality generation platform represents a potentially fundamental shift in what’s possible in the field of therapeutic development, addressing key challenges of drug discovery and drastically expanding the available search space for novel biomedicines. Generate Biomedicines was founded by Flagship Pioneering.

  • Chief Innovation Officer

    2018

  • Chief Strategy Officer

    2018 - 2023

KB

Kaleido Biosciences

  • Scientific Strategy and Operations

    2017 - 2018

  • Senior Scientist, Computational Biology

    2016 - 2018

  • Scientist, Computational Biology

    2015 - 2016

Kaleido BioSciences is a company working to design and analyze the microbiome system and provide adaptive solutions.

Raised $230,900,000.00 from Invus, Abu Dhabi Investment Authority, Rock Springs Capital, Fidelity and Flagship Pioneering.

kaleido.com
WU

Washington University School of Medicine

  • Ph.D. Candidate

    2010 - 2015

    - Demonstrated predictable community response of the developing preterm infant gut microbiota to antibiotic therapy, with robust resilience to specific antibiotics correlated with community-wide antibiotic resistance composition (Gibson et al, Nature Microbiology, 2016) - Developed Resfams, a profile hidden Markov model (HMM) database for improved annotation of antibiotic resistance in microbial genomes (Gibson et al, ISME, 2015) - Optimized ShortBRED for antibiotic resistance, a method for generating short markers of gene families to annotate functions using short read metagenomic sequencing data (Kaminski J*, Gibson MK*, et al., PLOS Comp. Biol., 2016) •- Supported by multiple competitive research fellowships (National Science Foundation Graduate Research Fellowship, Mr. & Mrs. Spencer T. Olin Fellowship)

B

Boeing

  • Software Engineer

    2009 - 2010

    - Software Engineer for F15-E Training Systems - Developed and maintained code that integrated software components into a fully functional software system - Wrote test procedures and documented test results to ensure software system requirements were met - Documented and maintained requirements, algorithms, interfaces and designs for software systems

Boeing Defense, Space & Security is a company that specializes in the advancement of different technological aspects.

boeing.com

Education 

Articles About Molly

Relevant Websites